http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Personalis Reports First Quarter 2021 Financial Results
-
Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®
-
Personalis Announces Collaboration with MapKure to Use Personalis’ NeXT Platform™ for Clinical Trials and Companion Diagnostic Development
-
Personalis Announces Changes to its Board of Directors
-
Personalis Reports Fourth Quarter and Full Year 2020 Financial Results
-
Natera and Personalis Partner for Personalized Monitoring in Oncology
-
Natera and Personalis Partner for Personalized Monitoring in Oncology
-
Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
-
Personalis Reports Preliminary Fourth Quarter 2020 Revenue
-
Personalis to Present at the 23rd Annual Needham Virtual Growth Conference
-
Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
-
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
-
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
-
Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
-
Personalis® to Present at the AMP Annual Meeting 2020
-
Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
-
Personalis Reports Third Quarter 2020 Financial Results
-
Personalis to Participate in Upcoming Investor Conferences
-
Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020
-
Personalis to Participate in Immuno Series US Virtual Meeting
-
Personalis, Inc. to Present at IO Combinations 360˚
-
Personalis to Participate in Digital World CB & CDx Meeting
-
Personalis, Inc. (PSNL) Receives Contract Extension and New Task Order From the VA’s Million Veteran Program
-
Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M
-
Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
-
Personalis to Participate in Upcoming Investor Conferences
-
Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
-
Personalis Reports Second Quarter 2020 Financial Results
-
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
-
Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Further Expands Leadership Team With Appointment of Leslie Grab, VP of Intellectual Property and John Lyle, VP of Assay Research and Development
-
Personalis Completes Sequencing 75,000th Whole Human Genome for VA MVP
-
Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting
-
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
-
Personalis to Present at the Precision Breast Cancer Summit
-
Personalis Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Personalis Announces a Partnership with Berry Genomics for China Expansion
-
Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
-
Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting
-
Personalis Reports First Quarter 2020 Financial Results
-
Personalis, Inc. Appoints Industry Veteran Stephen Moore as General Counsel
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
-
Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020
-
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
-
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
-
Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies
-
Personalis to Participate at the 19th Annual Needham Virtual Healthcare Conference
-
Personalis Reports Fourth Quarter and Full Year 2019 Financial Results

